chr11-64809695-G-C

Position:

• chr11-64809695-G-C

Variant summary

Our verdict is Pathogenic. Variant got 17 ACMG points: 17P and 0B. PM2 PM5 PP2 PP3_Strong PP5_Very_Strong

The NM_001370259.2(MEN1):​c.415C>G​(p.His139Asp) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. H139P) has been classified as Likely pathogenic.

• Frequency: Genomes: not found (cov: 31)
• Consequence: MEN1 NM_001370259.2 missense
• Clinical Significance: Pathogenic criteria provided, multiple submitters, no conflicts P:3
• Conservation: PhyloP100: 8.94

Genes affected

MEN1 (HGNC:7010): (menin 1) This gene encodes menin, a tumor suppressor associated with a syndrome known as multiple endocrine neoplasia type 1. Menin is a scaffold protein that functions in histone modification and epigenetic gene regulation. It is thought to regulate several pathways and processes by altering chromatin structure through the modification of histones. [provided by RefSeq, May 2019]

ACMG classification

Verdict is Pathogenic. Variant got 17 ACMG points.

• PM2: Very rare variant in population databases, with high coverage
• PM5: Other missense variant is known to change same aminoacid residue: Variant chrnull-null-null-null is described in UniProt as null.
• PP2: Missense variant in gene, where missense usually causes diseases (based on misZ statistic), MEN1. . Trascript score misZ 4.1921 (greater than threshold 3.09). GenCC has associacion of gene with multiple endocrine neoplasia type 1, pituitary gigantism, familial isolated hyperparathyroidism.
• PP3: MetaRNN computational evidence supports a deleterious effect, 0.992
• PP5: Variant 11-64809695-G-C is Pathogenic according to our data. Variant chr11-64809695-G-C is described in ClinVar as [Pathogenic]. Clinvar id is 16699.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr11-64809695-G-C is described in Lovd as [Pathogenic].

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	MANE	Protein	UniProt
MEN1	NM_001370259.2	c.415C>G	p.His139Asp	missense_variant	2/10	ENST00000450708.7	NP_001357188.2

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	TSL	MANE	Protein	Appris	UniProt
MEN1	ENST00000450708.7	c.415C>G	p.His139Asp	missense_variant	2/10	5	NM_001370259.2	ENSP00000394933	P3

Frequencies

GnomAD3 genomes Cov.: 31

GnomAD4 exome Cov.: 32

GnomAD4 genome Cov.: 31

ClinVar

Significance: Pathogenic

Submissions summary: Pathogenic:3

Revision: criteria provided, multiple submitters, no conflicts

Submissions by phenotype

Multiple endocrine neoplasia, type 1 Pathogenic:2

Pathogenic, no assertion criteria provided	literature only	OMIM	Dec 01, 2000	- -
Pathogenic, criteria provided, single submitter	clinical testing	Labcorp Genetics (formerly Invitae), Labcorp	Sep 08, 2021	Experimental studies have shown that this missense change affects MEN1 function (PMID: 9989505, 12509449, 14508515, 15254225, 21264250, 21819486, 22090276, 22275377, 22327296). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C15"). ClinVar contains an entry for this variant (Variation ID: 16699). This missense change has been observed in individuals with MEN1-related conditions (PMID: 9215689, 21917868). This variant is not present in population databases (ExAC no frequency). This sequence change replaces histidine with aspartic acid at codon 139 of the MEN1 protein (p.His139Asp). The histidine residue is highly conserved and there is a moderate physicochemical difference between histidine and aspartic acid. This variant disrupts the p.His139 amino acid residue in MEN1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 9215689, 30324798). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. -

Hereditary cancer-predisposing syndrome Pathogenic:1

Pathogenic, criteria provided, single submitter

clinical testing

Ambry Genetics

Dec 27, 2018

The p.H139D pathogenic mutation (also known as c.415C>G), located in coding exon 1 of the MEN1 gene, results from a C to G substitution at nucleotide position 415. The histidine at codon 139 is replaced by aspartic acid, an amino acid with some similar properties. This alteration has been previously identified in numerous individuals with multiple endocrine neoplasia type 1 (MEN1) (Stratakis et al. J Clin Endocrinol Metab. 2000 Dec; 85(12): 4776-80; Farrell WE et al. J Clin Endocrinol Metab. 2011 Nov;96(11):E1905-14; Ambry Internal Data). Functional studies have shown that this alteration leads to decreased MEN1 protein stability and abnormal transcriptional regulation of downstream targets (Shimazu S et al. Cancer Sci. 2011 Nov;102(11):2097-102; Agarwal SK et al. Hum Mol Genet.1997 Jul;6(7):1169-75; Canaff L et al. J Clin Endocrinol Metab. 2012 Feb;97(2):E282-91; Fang M et al. Mol. Cell. Biol., 2013 Jul;33:2635-47). Several other missense alterations at this codon (p.H139R, p.H139N, p.H139Q, p.H139P, p.H139Y) have also been identified in MEN1 probands (Martín-Campos JM et al. Diagn Mol Pathol. 1999 Dec;8(4):195-204; Cebrián A et al. J Med Genet. 2003 May;40(5):e72; Concolino P et al. Cancer Genet. 2016 Jan-Feb;209(1-2):36-41; Pardi E et al. PLoS One. 2017 Oct 16;12(10):e0186485; Carvalho RA et al. Eur J Endocrinol. 2018 Dec 1;179(6):391-407). Of note, this alteration is also designated c.525C>G in the published literature. Based on the available evidence, p.H139D is classified as a pathogenic mutation. -

Computational scores

Source: dbNSFP v4.3

Name	Calibrated prediction	Score	Prediction
AlphaMissense	Pathogenic	1.0
BayesDel_addAF	Pathogenic	0.56	D
BayesDel_noAF	Pathogenic	0.57
CADD	Pathogenic	33
DANN	Uncertain	0.99
DEOGEN2	Pathogenic	0.92	D;.;.;.;.;D;D;D;D;D;.;D;.;.
Eigen	Uncertain	0.51
Eigen_PC	Uncertain	0.49
FATHMM_MKL	Uncertain	0.94	D
LIST_S2	Uncertain	0.95	D;D;.;.;D;.;.;D;.;D;D;D;.;D
M_CAP	Pathogenic	0.85	D
MetaRNN	Pathogenic	0.99	D;D;D;D;D;D;D;D;D;D;D;D;D;D
MetaSVM	Pathogenic	1.1	D
MutationAssessor	Uncertain	2.6	.;M;M;M;M;M;M;M;M;.;.;.;.;.
MutationTaster	Benign	1.0	A;A;A;A;A;A;A;A;A;A
PrimateAI	Pathogenic	0.85	D
PROVEAN	Pathogenic	-8.2	D;D;D;D;D;D;D;D;D;D;D;D;D;D
REVEL	Pathogenic	0.94
Sift	Pathogenic	0.0	D;D;D;D;D;D;D;D;D;D;D;D;D;D
Sift4G	Pathogenic	0.0	D;D;D;D;D;D;D;D;D;.;D;D;.;.
Polyphen		0.039, 1.0	.;B;D;D;D;D;D;D;D;.;.;.;.;.
Vest4		0.90
MutPred		0.95		Gain of ubiquitination at K135 (P = 0.0436);Gain of ubiquitination at K135 (P = 0.0436);Gain of ubiquitination at K135 (P = 0.0436);Gain of ubiquitination at K135 (P = 0.0436);Gain of ubiquitination at K135 (P = 0.0436);Gain of ubiquitination at K135 (P = 0.0436);Gain of ubiquitination at K135 (P = 0.0436);Gain of ubiquitination at K135 (P = 0.0436);Gain of ubiquitination at K135 (P = 0.0436);Gain of ubiquitination at K135 (P = 0.0436);Gain of ubiquitination at K135 (P = 0.0436);Gain of ubiquitination at K135 (P = 0.0436);Gain of ubiquitination at K135 (P = 0.0436);Gain of ubiquitination at K135 (P = 0.0436);
MVP		1.0
MPC		2.5
ClinPred		1.0	D
GERP RS		4.9
Varity_R		0.97
gMVP		1.0

Splicing

Name	Calibrated prediction	Score	Prediction
SpliceAI score (max)		0.010		Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Other links and lift over

dbSNP: rs104894263; hg19: chr11-64577167;